ArticleDiscover oncology2026
IGF2BP3 promotes the muscle invasion of bladder cancer via PPARγ dysregulation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Bladder cancer (BC) is a common urinary-tract malignancy that, once it progresses to the muscle‐invasive form (MIBC), adopts a markedly more aggressive behavior and is linked to significantly poorer patient outcomes. Despite extensive investigation, the molecular drivers of MIBC progression have yet to be fully elucidated. In this study, we demonstrate that IGF2BP3 is markedly upregulated, whereas PPARγ is significantly downregulated, in MIBC tissues compared with non–muscle–invasive disease, and that these reciprocal expression changes correlate with enhanced muscle invasion and adverse clinical outcomes. Comprehensive in vitro analyses reveal that elevated IGF2BP3 modulates BC cell motility, with overexpression enhancing migration and invasion and knockdown reducing these processes, while effects on proliferation and apoptosis were minimal. Mechanistic investigations further indicate that IGF2BP3 manipulation in vitro modulates PPARγ mRNA levels and PPARγ knockdown or overexpression respectively augments or abrogates IGF2BP3‐driven cell motility. Collectively, our findings define a novel IGF2BP3/PPARγ signaling axis that contributes to the aggressive behavior of MIBC and suggest that targeting this pathway may offer new avenues for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.